Leerink Partnrs Lowers Earnings Estimates for ICON Public

ICON Public Limited (NASDAQ:ICLR) – Equities research analysts at Leerink Partnrs decreased their FY2025 earnings estimates for shares of ICON Public in a research note issued on Monday, March 3rd. Leerink Partnrs analyst M. Cherny now expects that the medical research company will earn $13.29 per share for the year, down from their prior estimate of $13.65. The consensus estimate for ICON Public’s current full-year earnings is $13.38 per share. Leerink Partnrs also issued estimates for ICON Public’s FY2026 earnings at $15.68 EPS and FY2027 earnings at $17.83 EPS.

ICON Public (NASDAQ:ICLR) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported $3.42 EPS for the quarter, beating the consensus estimate of $3.41 by $0.01. ICON Public had a net margin of 9.56% and a return on equity of 11.81%. The business had revenue of $2.04 billion for the quarter, compared to analyst estimates of $2.04 billion.

Other analysts have also recently issued research reports about the company. Leerink Partners reiterated an “outperform” rating and set a $255.00 price objective (down previously from $270.00) on shares of ICON Public in a research report on Tuesday, November 19th. Truist Financial lowered their price target on shares of ICON Public from $284.00 to $262.00 and set a “buy” rating for the company in a report on Thursday, February 13th. Barclays decreased their target price on shares of ICON Public from $275.00 to $240.00 and set an “overweight” rating on the stock in a research report on Friday, February 21st. Royal Bank of Canada reiterated an “outperform” rating and issued a $263.00 price target on shares of ICON Public in a report on Wednesday, January 15th. Finally, Citigroup decreased their price objective on ICON Public from $300.00 to $290.00 and set a “buy” rating on the stock in a report on Monday, January 6th. Four analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $279.17.

ICON Public Stock Performance

ICON Public stock opened at $186.49 on Wednesday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.34 and a current ratio of 1.26. ICON Public has a fifty-two week low of $179.50 and a fifty-two week high of $347.72. The stock has a fifty day moving average of $200.78 and a two-hundred day moving average of $238.28. The company has a market capitalization of $15.06 billion, a price-to-earnings ratio of 19.57, a PEG ratio of 1.86 and a beta of 1.21.

Hedge Funds Weigh In On ICON Public

A number of large investors have recently modified their holdings of the company. Sierra Ocean LLC acquired a new stake in ICON Public during the 4th quarter worth approximately $29,000. Park Place Capital Corp increased its position in shares of ICON Public by 281.4% in the fourth quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock worth $47,000 after acquiring an additional 166 shares in the last quarter. Private Trust Co. NA raised its stake in shares of ICON Public by 48.8% in the 4th quarter. Private Trust Co. NA now owns 250 shares of the medical research company’s stock valued at $52,000 after acquiring an additional 82 shares during the period. GAMMA Investing LLC lifted its holdings in shares of ICON Public by 64.0% during the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock valued at $91,000 after acquiring an additional 169 shares in the last quarter. Finally, First Horizon Advisors Inc. boosted its position in ICON Public by 33.9% during the 3rd quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock worth $172,000 after purchasing an additional 151 shares during the period. 95.61% of the stock is currently owned by hedge funds and other institutional investors.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.